From: MMP-1 expression has an independent prognostic value in breast cancer
Variable | Number of patients (%) |
---|---|
Number of the patients | 125 (aged 30-90, mean 57, 5) |
Grade | |
I | 10 (8%) |
II | 66 (52, 8%) |
III | 49 (39, 2%) |
Axillary nodal status | |
N0 | 64 (51, 2%) |
≥N1 | 50 (40%) |
Unknown | 11 (8, 8%) |
Estrogen receptor status (ER) 1) | |
Positive | 80 (64%) |
Negative | 45 (36%) |
Progesterone receptor status (PR) 1) | |
Positive | 82 (65, 6%) |
Negative | 43 (34, 4%) |
Ki-67 status 2) | |
low ≤ 15% | 63 (50,4%) |
intermediate 16-30% | 41 (32,8%) |
high > 30% | 20 (16%) |
one value missing | 1 (8%) |
Histologic type | |
Ductal | 110 (88%) |
Lobular | 10 (8%) |
Subtypes | 5 (4%) |
Her2 3) | |
IHC positive (2+ and 3+) | 25 (20%) |
IHC negative (0 and 1+) | 100 (80%) |
CK 5/6 4) | |
Triple-negative (ER-, PR-, Her2-) | 35 (28%) |
Basal-like carcinoma (ER-, PR-, Her2-, CK5/6+) | 20 (16%) |
Treatment after operation | |
Chemotherapy 27 | (21,6%) |
Radiation 59 | (47,2%) |
Hormonal therapy 24 | (19,2%) |